Edesa Biotech is trading 6.55% down at $3.85, primarily as biotech declines 2.11% during regular trading.

  • No new company-specific announcement was identified on September 16, 2026.
  • Its official news page lists the latest releases as the August 19, 2026 public-offering pricing and August 13, 2026 fiscal third-quarter results.
  • Sector sentiment worsened following disappointing drug-trial news and broader pressure on commercial-stage biotechnology stocks.